Covered recipient · General Payments record
FRANCIS J AVERILL
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$94,821.12
232 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,550.00 | 23 |
| Travel and Lodging | $21,539.32 | 36 |
| Consulting Fee | $8,048.00 | 1 |
| Food and Beverage | $5,408.15 | 169 |
| Education | $275.65 | 3 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $80,438.11 | 99 |
| Insmed, Inc. | $11,378.36 | 31 |
| GlaxoSmithKline, LLC. | $463.57 | 19 |
| Regeneron Healthcare Solutions, Inc. | $311.68 | 5 |
| JAZZ PHARMACEUTICALS INC. | $295.62 | 9 |
| GENZYME CORPORATION | $249.21 | 5 |
| HARMONY BIOSCIENCES LLC | $243.54 | 15 |
| Amgen Inc. | $212.67 | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $173.01 | 7 |
| United Therapeutics Corporation | $128.46 | 4 |
| Grifols USA, LLC | $120.44 | 5 |
| Actelion Pharmaceuticals US, Inc. | $119.41 | 2 |
| AstraZeneca UK Limited | $112.90 | 1 |
| ANI Pharmaceuticals, Inc. | $109.53 | 4 |
| Mannkind Corporation | $104.20 | 1 |
| Mallinckrodt Hospital Products Inc. | $99.45 | 3 |
| Novartis Pharmaceuticals Corporation | $76.51 | 3 |
| Merck Sharp & Dohme LLC | $44.76 | 2 |
| Bayer Healthcare Pharmaceuticals Inc. | $44.63 | 2 |
| 3B Medical, Inc. | $33.38 | 2 |
| IDORSIA PHARMACEUTICALS US INC | $23.63 | 1 |
| Paratek Pharmaceuticals, Inc. | $20.40 | 1 |
| Electromed, Inc. | $17.65 | 1 |
Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FRANCIS J AVERILL
NPI 1629005020 · CMS profile ID 299971
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
CLEARWATER, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FRANCIS J AVERILL, NPI 1629005020, CMS profile ID 299971. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). FRANCIS J AVERILL, NPI 1629005020, CMS profile ID 299971. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- FRANCIS J AVERILL, NPI 1629005020, CMS profile ID 299971, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
232 matching records · $94,821.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 232.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $18.40 | 10/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150223646 | CMS |
| Electromed, Inc. | $17.65 | 10/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137878411 | CMS |
| 3B Medical, Inc. | $13.09 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147571969 | CMS |
| Insmed, Inc. | $8.29 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089572052 | CMS |
| AstraZeneca Pharmaceuticals LP | $75.69 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110531379 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.95 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110535464 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.00 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110540471 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,128.24 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110550230 | CMS |
| AstraZeneca Pharmaceuticals LP | $74.00 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552510 | CMS |
| AstraZeneca Pharmaceuticals LP | $666.21 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110553280 | CMS |
| Merck Sharp & Dohme LLC | $28.23 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141633923 | CMS |
| GlaxoSmithKline, LLC. | $21.20 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116680591 | CMS |
| Paratek Pharmaceuticals, Inc. | $20.40 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 1113891638 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.25 | 10/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118084288 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 10/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110536902 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 10/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110548302 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,400.00 | 10/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110544755 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,387.23 | 10/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110543955 | CMS |
| AstraZeneca Pharmaceuticals LP | $838.68 | 10/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110547406 | CMS |
| AstraZeneca Pharmaceuticals LP | $103.46 | 10/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110551552 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.82 | 09/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110540287 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 09/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110543953 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.94 | 09/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110548974 | CMS |
| Insmed, Inc. | $6.12 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089557388 | CMS |
| JAZZ PHARMACEUTICALS INC. | $27.13 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150223656 | CMS |
| Harmony Biosciences Llc | $21.23 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141477914 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,800.00 | 09/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110551970 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.61 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114002374 | CMS |
| AstraZeneca Pharmaceuticals LP | $80.77 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110544697 | CMS |
| AstraZeneca Pharmaceuticals LP | $803.61 | 09/16/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110554190 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.29 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118084290 | CMS |
| Amgen Inc. | $19.35 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111520879 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.93 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110555070 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.78 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552916 | CMS |
| Insmed, Inc. | $18.06 | 09/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089557352 | CMS |
| GlaxoSmithKline, LLC. | $29.97 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115824862 | CMS |
| Mallinckrodt Hospital Products Inc. | $38.70 | 08/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145047793 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,750.00 | 08/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110542997 | CMS |
| HARMONY BIOSCIENCES LLC | $22.39 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126061430 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.45 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110551554 | CMS |
| JAZZ PHARMACEUTICALS INC. | $26.02 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150223660 | CMS |
| JAZZ PHARMACEUTICALS INC. | $99.00 | 08/27/2024 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155980455 | CMS |
| Regeneron Healthcare Solutions, Inc. | $86.66 | 08/27/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114002372 | CMS |
| Amgen Inc. | $18.92 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111520877 | CMS |
| GlaxoSmithKline, LLC. | $21.20 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116484505 | CMS |
| United Therapeutics Corporation | $23.78 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149470532 | CMS |
| 3B Medical, Inc. | $20.29 | 08/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147571965 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.78 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110539891 | CMS |
| Insmed, Inc. | $23.25 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089557918 | CMS |
| Grifols USA, LLC | $24.72 | 08/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1124747065 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,079,226.22 | 361 |
| PY2024 | Principal investigator | $1,630,664.43 | 339 |
| PY2023 | Recipient | $37,250.49 | 8 |
| PY2023 | Principal investigator | $961,208.18 | 218 |
| PY2022 | Principal investigator | $433,875.64 | 120 |
| PY2021 | Recipient | $74.51 | 1 |
| PY2021 | Principal investigator | $669,758.16 | 155 |
| PY2020 | Recipient | $34.82 | 1 |
| PY2020 | Principal investigator | $485,724.55 | 143 |
| PY2019 | Recipient | $15,237.70 | 9 |
| PY2019 | Principal investigator | $623,053.67 | 58 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
361 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GlaxoSmithKline, LLC. | $693.80 | 12/24/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192165365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,271.81 | 12/24/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184280234 |
| Principal investigator 1 | United Therapeutics Corporation | $1,704.30 | 12/24/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388303 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646646 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646648 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646650 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646652 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646654 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646656 |
| Principal investigator 1 | Insmed, Inc. | $150.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646658 |
| Principal investigator 1 | Insmed, Inc. | $250.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646660 |
| Principal investigator 1 | Insmed, Inc. | $250.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646662 |
| Principal investigator 1 | Insmed, Inc. | $250.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646664 |
| Principal investigator 1 | Insmed, Inc. | $630.00 | 12/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646668 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.00 | 12/17/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799606 |
| Principal investigator 1 | Genentech, Inc. | $1,300.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658976 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658980 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658983 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658987 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658991 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658995 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211658999 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659003 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659007 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659011 |
| Principal investigator 1 | Genentech, Inc. | $405.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659016 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659019 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659026 |
| Principal investigator 1 | Genentech, Inc. | $270.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659030 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659034 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659037 |
| Principal investigator 1 | Genentech, Inc. | $135.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659042 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659046 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659051 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659054 |
| Principal investigator 1 | Genentech, Inc. | $270.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659059 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659062 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659068 |
| Principal investigator 1 | Insmed, Inc. | $2,000.00 | 12/17/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646666 |
| Principal investigator 1 | Insmed, Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646670 |
| Principal investigator 1 | Insmed, Inc. | $1,400.00 | 12/17/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646672 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 12/15/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799624 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 12/15/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799626 |
| Principal investigator 1 | Genentech, Inc. | $7,032.00 | 12/11/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659168 |
| Principal investigator 1 | Genentech, Inc. | $34,126.00 | 12/11/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211659173 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.00 | 12/10/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799600 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.00 | 12/10/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799602 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.00 | 12/10/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799604 |
| Principal investigator 1 | Mannkind Corporation | $2,500.00 | 12/10/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898672 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,956.20 | 12/03/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 12/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 12/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 12/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 12/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 12/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 12/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 12/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.39 | 12/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724785 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 12/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791671 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 12/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791673 |
| Principal investigator 1 | United Therapeutics Corporation | $331.20 | 11/26/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388293 |
| Principal investigator 1 | United Therapeutics Corporation | $1,524.90 | 11/26/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388301 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,288.00 | 11/24/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192163802 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,676.00 | 11/24/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192163806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,247.28 | 11/19/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $198.72 | 11/19/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262497 |
| Principal investigator 1 | United Therapeutics Corporation | $5,023.20 | 11/12/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 11/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 11/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 11/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 11/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 11/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 11/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 11/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.39 | 11/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724777 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 11/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791667 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 11/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 10/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622770 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 10/27/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 10/27/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.64 | 10/27/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 10/27/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724793 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,081.40 | 10/23/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192165368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $198.72 | 10/17/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251379 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,215.92 | 10/17/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251381 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,397.50 | 10/02/2025 | Non-covered Recipient Entity SAINT FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185555820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 10/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 10/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 10/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 10/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.39 | 10/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 10/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 10/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 10/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $850.00 | 09/26/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184243125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,483.00 | 09/26/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184243127 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,660.00 | 09/26/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184243129 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $974.00 | 09/26/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184243131 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 09/24/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799568 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,810.00 | 09/24/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799570 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/24/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799572 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 09/24/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799574 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $207.60 | 09/24/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799576 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,710.04 | 09/18/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184240292 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,463.20 | 09/18/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184240294 |
| Principal investigator 1 | Mannkind Corporation | $4,922.43 | 09/16/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898580 |
| Principal investigator 1 | United Therapeutics Corporation | $2,208.00 | 09/10/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388305 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,222.60 | 09/08/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192163809 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $276.00 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799549 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799551 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799553 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799555 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799557 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799559 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799561 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799564 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/04/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220799566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 09/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 09/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 09/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 09/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.39 | 09/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 09/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 09/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 09/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724759 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 09/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791663 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 09/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791665 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/01/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799612 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/01/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799614 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/01/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799616 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/01/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799618 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.60 | 09/01/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799620 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,250.00 | 08/28/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799598 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $693.80 | 08/27/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192163821 |
| Principal investigator 1 | United Therapeutics Corporation | $483.00 | 08/27/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388295 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,015.80 | 08/22/2025 | Non-covered Recipient Entity SAINT FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185555826 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,858.50 | 08/21/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $557.66 | 08/20/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184228859 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 08/14/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646634 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 08/14/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646638 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 08/14/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646642 |
| Principal investigator 1 | Mannkind Corporation | $17,053.36 | 08/12/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898540 |
| Principal investigator 1 | Mannkind Corporation | $10,046.40 | 08/12/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898542 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 08/07/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646636 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 08/07/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646640 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 08/07/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 08/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 08/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 08/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 08/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.39 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $335.63 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724751 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 08/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791659 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 08/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791661 |
| Principal investigator 1 | Genentech, Inc. | $1,634.00 | 07/23/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659163 |
| Principal investigator 1 | Genentech, Inc. | $27,453.00 | 07/22/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659158 |
| Principal investigator 1 | Genentech, Inc. | $550.00 | 07/09/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659155 |
| Principal investigator 1 | United Therapeutics Corporation | $3,229.20 | 07/08/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388309 |
| Principal investigator 1 | Genentech, Inc. | $309.00 | 07/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 07/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 07/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 07/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 07/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $799.00 | 07/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 07/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 07/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 07/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 07/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 07/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724761 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 07/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791655 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 07/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791657 |
| Principal investigator 1 | United Therapeutics Corporation | $331.20 | 06/25/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,500.00 | 06/24/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184210544 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,535.00 | 06/23/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184210340 |
| Principal investigator 1 | Insmed, Inc. | $0.66 | 06/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646620 |
| Principal investigator 1 | Insmed, Inc. | $11,481.40 | 06/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646624 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 06/19/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646628 |
| Principal investigator 1 | Insmed, Inc. | $0.66 | 06/12/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646622 |
| Principal investigator 1 | Insmed, Inc. | $11,481.40 | 06/12/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646626 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 06/12/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646630 |
| Principal investigator 1 | United Therapeutics Corporation | $2,691.00 | 06/11/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 06/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 06/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 06/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 06/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 06/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 06/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 06/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 06/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.90 | 06/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.28 | 06/01/2025 | Non-covered Recipient Entity St Francis Sleep Allergy And Lung Institute LLC | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220724723 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 06/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791651 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 06/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791653 |
| Principal investigator 1 | Genentech, Inc. | $120.00 | 05/28/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659115 |
| Principal investigator 1 | Genentech, Inc. | $42.00 | 05/23/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659085 |
| Principal investigator 1 | Genentech, Inc. | $42.00 | 05/23/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659118 |
| Principal investigator 1 | Genentech, Inc. | $120.00 | 05/23/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659121 |
| Principal investigator 1 | Genentech, Inc. | $120.00 | 05/23/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659129 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $498.00 | 05/16/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799586 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500.00 | 05/16/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799588 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.00 | 05/16/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799590 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,939.00 | 05/16/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799592 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,900.00 | 05/16/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799594 |
| Principal investigator 1 | Genentech, Inc. | $51,485.00 | 05/13/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659101 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,135.70 | 05/09/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799584 |
| Principal investigator 1 | United Therapeutics Corporation | $1,524.90 | 05/07/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388299 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659077 |
| Principal investigator 1 | Genentech, Inc. | $120.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659081 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659089 |
| Principal investigator 1 | Genentech, Inc. | $120.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659106 |
| Principal investigator 1 | Genentech, Inc. | $120.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659111 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659125 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659133 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659138 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659143 |
| Principal investigator 1 | Genentech, Inc. | $2,399.00 | 05/02/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $37.66 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $37.66 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622712 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791647 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791649 |
| Principal investigator 1 | Genentech, Inc. | $8,554.00 | 05/01/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $557.66 | 04/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184190505 |
| Principal investigator 1 | Amgen Inc. | $34,169.00 | 04/24/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246648605 |
| Principal investigator 1 | Mannkind Corporation | $15,638.86 | 04/18/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898488 |
| Principal investigator 1 | Mannkind Corporation | $15,312.83 | 04/18/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898490 |
| Principal investigator 1 | Mannkind Corporation | $18,578.26 | 04/18/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898492 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $40.00 | 04/17/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192163817 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.03 | 04/17/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192163825 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,900.00 | 04/17/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192165386 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,688.40 | 04/10/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799610 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 04/09/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646616 |
| Principal investigator 1 | United Therapeutics Corporation | $897.00 | 04/09/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388297 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 04/02/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646614 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 04/02/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646618 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 04/02/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 04/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 04/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622800 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 04/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791643 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 04/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220791645 |
| Principal investigator 1 | Genentech, Inc. | $34,363.00 | 04/01/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659097 |
| Principal investigator 1 | Mannkind Corporation | $255.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898456 |
| Principal investigator 1 | Mannkind Corporation | $255.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898458 |
| Principal investigator 1 | Mannkind Corporation | $255.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898460 |
| Principal investigator 1 | Mannkind Corporation | $3,350.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898462 |
| Principal investigator 1 | Mannkind Corporation | $2,075.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898464 |
| Principal investigator 1 | Mannkind Corporation | $2,025.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898466 |
| Principal investigator 1 | Mannkind Corporation | $150.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898468 |
| Principal investigator 1 | Mannkind Corporation | $1,200.00 | 03/28/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898470 |
| Principal investigator 1 | Insmed, Inc. | $0.88 | 03/27/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646544 |
| Principal investigator 1 | Insmed, Inc. | $16,073.96 | 03/27/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646548 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 03/27/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646566 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,620.00 | 03/25/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799582 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,896.05 | 03/20/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192163813 |
| Principal investigator 1 | Insmed, Inc. | $1.33 | 03/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646546 |
| Principal investigator 1 | Insmed, Inc. | $16,073.96 | 03/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646550 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 03/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646552 |
| Principal investigator 1 | Insmed, Inc. | $1.38 | 03/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646568 |
| Principal investigator 1 | Paratek Pharmaceuticals, Inc. | $228.00 | 03/20/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | No dispute reported | 06/30/2026 | 1181711142 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,750.50 | 03/18/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799580 |
| Principal investigator 1 | Paratek Pharmaceuticals, Inc. | $3,122.94 | 03/13/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | No dispute reported | 06/30/2026 | 1181711136 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,576.73 | 03/07/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 1192108973 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $804.00 | 03/07/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192165377 |
| Principal investigator 1 | Paratek Pharmaceuticals, Inc. | $2,985.53 | 03/06/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | No dispute reported | 06/30/2026 | 1181711118 |
| Principal investigator 1 | Paratek Pharmaceuticals, Inc. | $4,524.00 | 03/06/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | No dispute reported | 06/30/2026 | 1181711120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 03/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 03/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.79 | 03/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.79 | 03/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622804 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 03/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220791639 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 03/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220791641 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 02/27/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646540 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 02/27/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646554 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 02/27/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646558 |
| Principal investigator 1 | United Therapeutics Corporation | $1,794.00 | 02/26/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.68 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622694 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.50 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220622696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.02 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.60 | 02/25/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622836 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,622.22 | 02/24/2025 | Non-covered Recipient Entity ST FRANCIS INSTITUTE | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185555824 |
| Principal investigator 1 | Insmed, Inc. | $1,304.55 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646596 |
| Principal investigator 1 | Insmed, Inc. | $1,304.55 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646598 |
| Principal investigator 1 | Insmed, Inc. | $1,374.75 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646600 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646602 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646604 |
| Principal investigator 1 | Insmed, Inc. | $70.20 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646606 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646608 |
| Principal investigator 1 | Insmed, Inc. | $263.25 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646610 |
| Principal investigator 1 | Insmed, Inc. | $46.80 | 02/21/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646612 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 02/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646542 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 02/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646556 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 02/20/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646560 |
| Principal investigator 1 | United Therapeutics Corporation | $2,960.10 | 02/12/2025 | Non-covered Recipient Entity St Francis Holdings LLC | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242388289 |
| Principal investigator 1 | Genentech, Inc. | $40,683.00 | 02/06/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659074 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 02/05/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646562 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 02/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 02/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 02/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 02/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622792 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 02/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220791635 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 02/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220791637 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,179.21 | 01/30/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192165381 |
| Principal investigator 1 | Amgen Inc. | $3,265.72 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDICAL INSTITUTE | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246648608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622810 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.04 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.20 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.20 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.20 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.20 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.20 | 01/27/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220622822 |
| Principal investigator 1 | Insmed, Inc. | $1,567.80 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646570 |
| Principal investigator 1 | Insmed, Inc. | $1,567.80 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646572 |
| Principal investigator 1 | Insmed, Inc. | $1,567.80 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646574 |
| Principal investigator 1 | Insmed, Inc. | $1,714.05 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646576 |
| Principal investigator 1 | Insmed, Inc. | $1,257.75 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646578 |
| Principal investigator 1 | Insmed, Inc. | $1,374.75 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646580 |
| Principal investigator 1 | Insmed, Inc. | $1,374.75 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646582 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646584 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646586 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646588 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646590 |
| Principal investigator 1 | Insmed, Inc. | $298.35 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646592 |
| Principal investigator 1 | Insmed, Inc. | $263.25 | 01/24/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646594 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 01/23/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646564 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,736.80 | 01/21/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220799608 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,539.00 | 01/13/2025 | Non-covered Recipient Entity Saint Francis Sleep Allergy And Lung Institute | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235994111 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,075.75 | 01/13/2025 | Non-covered Recipient Entity ST FRANCIS HOLDINGS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192165373 |
| Principal investigator 1 | Insmed, Inc. | $1.33 | 01/13/2025 | Non-covered Recipient Entity St. Francis Medical Institute - Clinedge - PPDS | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646538 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $297,116.81 | 01/09/2025 | Non-covered Recipient Entity Saint Francis Sleep Allergy And Lung Institute | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235994109 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,787.67 | 01/08/2025 | Non-covered Recipient Entity SAINT FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185555822 |
| Principal investigator 1 | Genentech, Inc. | $9,951.00 | 01/08/2025 | Non-covered Recipient Entity ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211659071 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,464.30 | 01/06/2025 | Non-covered Recipient Entity St Francis Holdings LLC St Francis Medical Institute | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220799578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220622784 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220791631 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 01/01/2025 | Non-covered Recipient Entity ST FRANCIS MEDCL INST | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220791633 |